Accession Therapeutics

4:45 PM - 5:00 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104B
Accession Therapeutics is developing a new generation of immunotherapies for solid tumors.
Accession Therapeutics aims to address tumor diversity using its highly potent universal bispecific drugs, expressed only in cancer cells.
Company objectives: deliver first-in-human clinical trials 1H 2024 and seek a partnership for later stage trials and commercialisation.
We aim to deliver a step change in cancer treatments for patients with solid tumors.
Company Type:
Privately Funded Company
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Trocept 1
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Accession Therapeutics LTD